FR194738 is a squalene epoxidase inhibitor used to suppress cholesterol biosynthesis by inhibiting squalene epoxidase activity in vitro and in vivo; it reduces serum levels of total cholesterol, non-HDL cholesterol, HDL cholesterol, and triglycerides in hamsters; it is more potent than HMG-CoA reductase inhibitors (e.g., simvastatin, fluvastatin, pravastatin) in inhibiting cholesterol synthesis in HepG2 cells.